Vanda Pharmaceuticals’ Phase III trial of VQW-765 in social anxiety disorder failed its primary endpoint with a margin so thin it barely registers: female participants who received the drug scored 65.6 on the Subjective Units of Distress Scale during a standardized public speaking challenge, versus 66.0 for placebo, a difference of -0.4 points that carried a p-value of 0.89. The full-population secondary endpoint fared no better, with the drug group actually scoring slightly higher than placebo. Study 3201 enrolled 546 adults across roughly 30 U.S. sites, making it a substantial bet on a mechanism that had shown only numerical, not statistically significant, benefit in Phase II.
That Phase II signal, published in the British Journal of Psychiatry in 2025, was the entire rationale for pressing forward. Study 2201 enrolled 230 adults with a history of public speaking anxiety and found numerically lower stress scores in the VQW-765 arm under the same Trier Social Stress Test conditions. The Phase III design was built to confirm that finding, particularly in women, which is why the primary endpoint was scoped to female participants. It did not confirm it, in either subgroup or the combined population.
VQW-765 is an alpha-7 nicotinic acetylcholine receptor partial agonist, licensed from Novartis and developed specifically for on-demand use, meaning patients would take a single oral dose before an anxiety-provoking event rather than on a daily maintenance schedule. That design, attractive for a condition tied to discrete situations like job interviews or public performances, rested on the assumption that the receptor pathway would produce a detectable anxiolytic effect acutely. The Phase III data suggest it does not, at least not at a level separable from placebo in a 546-person trial using a well-validated stress induction model.
The program is now on hold while Vanda analyzes the full dataset. Whether that review yields a subgroup or biomarker hypothesis worth pursuing is the only question that matters for the compound’s future, and the near-total absence of separation between arms makes a path forward difficult to construct.
VQW-765: the facts in one place
- Also written: AQW-051
- Sponsor: Vanda Pharmaceuticals Inc.
- Mechanism: alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist
- Indication studied: acute anxiety in adults with social anxiety disorder (on-demand treatment)
- Phase: Phase III
- Enrollment: 546
- Primary endpoint: Subjective Units of Distress Scale (SUDS) scores in female participants during a Trier Social Stress Test
- Headline result: Primary endpoint not met; SUDS scores 65.6 (VQW-765) vs 66.0 (placebo), p=0.8899; key secondary endpoint in combined male and female population also failed
- Registry identifier: NCT07221578
- Current status: Program on hold as of October 14, 2026, pending further analysis of the full dataset
- Phase III trial last modified on ClinicalTrials.gov: July 25, 2026
- Program placed on hold: October 14, 2026
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
